Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.

A consistent and highly significant reduction of ALP levels was observed following GFT505 treatment in both studies (S1 −16.4% [−∞ to −12.4]; S2 −24.5% [−∞ to −19.1], all P < 0.0001) ( Tables 2 and 3 and Fig. 1 D ).

also in 132,142 other papers